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Staphylococcus aureus
 
 is a major pathogen of gram-positive septic shock and frequently is 
associated with consumption of plasma kininogen. We examined the vascular leakage (VL) 
activity of two cysteine proteinases that are secreted by 
 
S. aureus
 
. Proteolytically active 
staphopain A (ScpA) induced VL in a bradykinin (BK) B
 
2
 
-receptor–dependent manner in 
guinea pig skin. This effect was augmented by staphopain B (SspB), which, by itself, had no 
VL activity. ScpA also produced VL activity from human plasma, apparently by acting directly 
on kininogens to release BK, which again was augmented significantly by SspB. Intravenous 
injection of ScpA into a guinea pig caused BK B
 
2
 
-receptor–dependent hypotension. ScpA and 
SspB together induced the release of leucyl-methionyl-lysyl-BK, a novel kinin with VL and 
blood pressure–lowering activities that are equivalent to BK. Collectively, these data suggest 
that production of BK and leucyl-methionyl-lysyl-BK by staphopains is a new mechanism of 
 
S. aureus
 
 virulence and bacterial shock. Therefore, staphopain-specific inhibitors and kinin-
receptor antagonists could be used to treat this disease.
 
Recent clinical studies revealed that gram-
positive bacteria are as common as gram-nega-
tive bacteria in causing sepsis (1, 2) that often
leads to septic shock, a condition with a high
mortality, despite improved antibiotic therapy
and intensive care. The pathogenesis of septic
shock by gram-positive bacteria has not been
elucidated fully. However, the plasma levels of
the plasma kallikrein/kinin system components,
factor XII, prekallikrein, and high molecular
weight kininogen (HK), are low in patients who
have sepsis (3–6); this indicates activation and
subsequent consumption of these components.
The activation of the plasma kallikrein/kinin
system in an animal bacteremia model causes
lethal hypotension (7, 8); hence, plasma kal-
likrein/kinin system activation seems to con-
tribute to septic shock.
 
Staphylococcus aureus
 
 is the most frequently
isolated pathogen in gram-positive sepsis (1,
9), which suggests that some factor from this
bacterium is associated with septic shock in-
duction. In human plasma, 
 
S. aureus
 
 induces
the release of bradykinin (BK; reference 10),
the final product of plasma kallikrein/kinin
system activation which causes vascular leakage
(VL; reference 11) and leads to hypotension.
This bacterium has a high negative net surface
charge because of the presence of cell wall te-
ichoic acid and lipoteichoic acid (12), and can
activate the plasma kallikrein/kinin system as
efficiently as LPS and lipid A from gram-nega-
tive bacteria in vitro (13). Thus, these cell wall
molecules also may activate the plasma kal-
likrein/kinin system in 
 
S. aureus
 
 bacteremia.
However, heat-labile extracellular products of
 
S. aureus
 
 are far more potent than the cell wall
components as lethal factors in the mouse sepsis
model (14).
In addition to enterotoxins and hemo-
lysins, 
 
S. aureus
 
 secretes several extracellular
proteinases (15) that may play a role in septic
shock. The V8 proteinase can release kinin
from HK. This activity is not abolished in the
presence of serine proteinase inhibitors (16);
this suggests that other than the V8 proteinase,
contaminating proteolytic activity may have
been responsible for kinin generation. Stapho-
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pains A and B (ScpA and SspB) are 
 
S. aureus
 
–derived cys-
teine proteinases. Their papainlike character has been inves-
tigated thoroughly with respect to molecular structure and
posttranslational processing of proenzymes and led to the
generation of 21-kD mature proteinases (17–20). Therefore,
we purified these two cysteine proteinases from 
 
S. aureus
 
culture medium and examined their VL and blood pressure
(BP)-lowering activities. ScpA, especially in concert with
SspB, possessed strong VL activity and lowered BP. The re-
sults indicate a new virulence mechanism in which stapho-
pains liberate kinins, including a novel kinin that is released
through alternative cleavage of kininogens. We believe that
staphopains may be involved in septic shock that is caused by
 
S. aureus
 
 infection.
 
RESULTS
Induction of VL by ScpA
 
ScpA induced VL in a dose-dependent manner starting at an
enzyme concentration of 20 nM. In contrast to a linear in-
crease of VL that is caused by exponentially increased doses
of BK, the VL reaction that was triggered by ScpA injection
increased steeply at higher enzyme concentrations (Figs. 1
and 2). Because ScpA showed no VL activity when inacti-
vated by E-64, a cysteine proteinase inhibitor, the pro-
teolytic activity of the enzyme is linked to production of VL
activity (Figs. 1 and 2). Despite the lack of any significant VL
activity, SspB increased ScpA-induced VL in a dose-depen-
dent manner, whereas the proteinase exhibited no such ef-
fect on BK-induced VL (Fig. 2). HOE140, a BK B
 
2
 
 receptor
antagonist, strongly inhibited VL that was induced by ScpA,
a mixture of ScpA and SspB, or BK, but not the reaction
that was caused by histamine (Fig. 2, inset). The dependency
of staphopain VL activity on this receptor suggests kinin re-
lease through activation of the factor XII-prekallikrein-kinin-
ogen system by staphopains. At 600 nM, ScpA caused for-
mation of a large blue spot on the guinea pig skin. This
reaction contrasts with spots that were formed in response to
BK, which increased only slightly when the dose of BK was
increased by three orders of magnitude (Fig. 1). To explain
this phenomenon, we calculated the ratio of the blue spot
area (in mm
 
2
 
) to the amount of dye that was extracted from
the skin (in 
 
 
 
g). Although higher doses of BK and gingipain
R, a bacterial proteinase that is known to elicit strong VL re-
action (21), increased dye extravasation, the ratio of the blue
Figure 1. Induction of vascular permeability enhancement by staph-
opains. 100  l of staphopain A or B or BK was injected intradermally into
a guinea pig that previously received Evans blue dye. a, ScpA (600 nM); 
b, ScpA (200 nM); c, ScpA (60 nM); d, ScpA (20 nM); e, ScpA (600 nM) treated 
with E-64 (50  M for 30 min); f, SspB (600 nM); g, bradykinin (1  M); 
h, bradykinin (100 nM); i, bradykinin (10 nM); j, 10 mM tris-buffered saline.
Figure 2. Leaked dye of each blue spot. ( ), ScpA; ( ), SspB; ( ), BK; 
( ), BK (100 nM)   SspB; ( ), ScpA (60 nM)   SspB; ( ), ScpA treated 
with E-64 (50  M). *P   0.01 for ScpA 200 nM versus 60 nM or 600 nM; 
for ScpA 60 nM   SspB 60 nM versus ScpA 60 nM   SspB 600 nM; and 
for BK 10 nM versus 100 nM. **P   0.03 for BK 100 nM versus 1000 nM. 
Inset, the effect of HOE140 on VL activity that was induced by stapho-
pains, BK, or histamine. Guinea pigs were injected with HOE140 (10 nmol/kg 
body weight) 30 min before intradermal injection of samples. (White bars) 
Without HOE140 treatment; (black bars) with HOE140 treatment. A, ScpA 
300 nM; A B, ScpA 60 nM   SspB 600 nM; BK, bradykinin 1  M; HS, his-
tamine 10  M. Values are means   SD (n   3). *P   0.01 for with versus 
without HOE140 treatment.
Figure 3. Leaked area vs. leaked dye amount. The spot area (mm2) 
was divided by the dye amount ( g) that was extracted from the spot. 
Values are means   SD (n   3). *P   0.001. 
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spot area to the amount of dye was constant (
 
 
 
2.5; Fig. 3).
In contrast, in the case of ScpA-induced VL, the ratio was
much greater and dependent on enzyme concentration (Fig.
3). This suggests an excessive spread of leaked plasma which
carried Evans blue to the extravascular space in the connec-
tive tissue of the guinea pig skin after ScpA injection.
 
Production of VL activity from human plasma by ScpA
 
ScpA generated VL activity from normal human plasma in a
dose- and activity-dependent manner when incubated for
only 5 min (Fig. 4). SspB did not produce VL activity by
itself; however, the enzyme significantly increased ScpA-
induced VL activity production from human plasma (Fig. 4).
The inhibitory effect of HOE140 on VL induction by direct
ScpA injection into the guinea pig skin (Fig. 2, inset) and VL
activity production from human plasma by ScpA, alone, or
with both staphopains administered together (Fig. 4), indi-
cated dependence of the VL reaction on the BK B
 
2
 
-recep-
tor. To identify the target protein of staphopains, we investi-
gated the generation of VL activity by ScpA in plasmas that
were deficient in factor XII, prekallikrein, or kininogens.
ScpA produced VL activity from plasmas that were deficient
in factor XII or prekallikrein, almost equivalent to the activ-
ity that was produced from normal plasma, but not from
kininogen-deficient plasma (Fig. 4, inset). This suggested the
direct action of ScpA on kininogen. To confirm this, we in-
vestigated the ScpA-dependent VL generation in kininogen-
deficient plasma that was supplemented with physiologic
concentrations of kininogens (22). ScpA induced VL activity
from HK reconstituted kininogen-deficient plasma, which
was increased further by the addition of low molecular
weight kininogen (LK) to a level of the normal plasma con-
centration (Fig. 4, inset). Together, these data indicate that
both kininogens are the major targets of staphopains, and ac-
tivation of factor XII or prekallikrein contributes negligibly
to the VL activity production.
 
Production of VL activity from human kininogens by 
staphopain A
 
To determine whether ScpA can produce VL activity from
kininogens, we incubated purified human kininogens with
the enzyme and measured VL activity. ScpA produced VL
activity in a dose-dependent manner from both kininogens;
it yielded more VL activity from LK than HK when used at
their physiologic plasma concentrations (Fig. 5). SspB did
not generate VL activity from HK, but augmented the
ScpA-induced VL activity production in a dose-dependent
manner (Fig. 5, inset). Consistent with previous results (Figs.
2, inset, and 4), HOE140 completely abolished VL activity
that was generated from each kininogen by ScpA or by a
combination of the two staphopains (Fig. 5). Preincubation
of factor XII or prekallikrein with ScpA did not induce sig-
nificant VL (Fig. 5) or hydrolysis of fluorogenic substrates
Figure 4. Production of VL activity from various human plasmas by 
staphopains. 45  l of normal human plasma, supplemented with 1 mM 
1,10-phenanthroline to inhibit kininases, was incubated with 5  l of
staphopain at 37 C for 5 min, followed by the addition of 50  l of 10 mM 
Tris-HCl, pH 7.3, containing 150 mM NaCl, supplemented with 0.1 mM 
E-64, 1 mM 1.10-phenanthroline, and 20  M SBTI. Each sample (100  l) 
was measured for VL activity. ScpA in the absence ( ) or presence ( ) of 
HOE140; ( ), SspB; ( ), ScpA treated with E-64 (50  M); ScpA (0.3  M)   
SspB (0.6  M) in the absence ( ) or presence ( ) of HOE140. Values
are means   SD (n   3). *P   0.01 for ScpA 0.1  M versus 0.3  M. 
**P   0.02 for ScpA 0.3  M versus 1  M. ***P   0.03 for ScpA 0.3  M 
versus ScpA 0.3  M   SspB 0.6  M. (Inset) Deficient plasmas with or 
without reconstitution of the missing protein were incubated with 1  M 
staphopain A and VL activity was measured. a, normal human plasma; 
b, factor XII-deficient plasma; c, prekallikrein-deficient plasma; d, kininogen-
deficient plasma; e, kininogen-deficient plasma reconstituted with HK 
(80  g/ml); f, kininogen-deficient plasma reconstituted with HK (80  g/
ml) and LK (130  g/ml). Values are means   SD (n   3). *P   0.005 for d 
versus e. **P   0.03 for e versus f.
Figure 5. Production of VL activity from kallikrein/kinin system 
components by staphopains. 10  l of ScpA and 90  l of TBS which con-
tained factor XII (40  g/ml), prekallikrein (40  g/ml), HK (80  g/ml), LK 
(130  g/ml), or both kininogens was incubated at 37 C for 10 min; 5  l of 
1 mM E-64 was added to stop the reaction. Each sample (100  l) was 
measured for VL activity. ( ), factor XII; ( ), prekallikrein; ( ), HK; ( ), 
LK; ( ), HK LK. Closed symbols denote VL activity in HOE140-treated 
guinea pigs. Values are means   SD (n   3). *P   0.05 for LK versus HK   
LK at ScpA 10 and 30 nM, and for LK versus HK at ScpA 100 nM. (Inset) The 
effect of HOE140 on VL activity that was induced from HK by a combina-
tion of ScpA (30 nM) and SspB in the absence ( ) or presence ( ) of 
HOE140. ( ), ScpA (30 nM) alone. Values are means   SD (n   3). *P   0.05 
for ScpA 30 nM alone versus ScpA 30 nM   SspB 30 nM. **P   0.02 for 
ScpA 30 nM   SspB 30 nM versus ScpA 30 nM   SspB 300 nM.S. AUREUS PROTEINASES INCREASE VASCULAR LEAKAGE | Imamura et al. 1672
that were specific for each activated form (not depicted); this
indicated that ScpA does not activate these zymogens. These
results indicate that staphopains cleave kininogens and re-
lease a peptide(s) that can induce VL through an interaction
with the BK B2-receptor. The ability of staphopains to
cleave HK and LK was confirmed by SDS-PAGE analysis of
the mixture of kininogens that were preincubated with
staphopains at the weight ratio in the range from 50:1 to 5:1
(Fig. 6). LK was cleaved at the COOH terminus only by
SspB, as recognized by a slight reduction of the molecular
mass of the protein. Conversely, HK was degraded by both
staphopains; SspB was more efficient than ScpA. In both
cases, kininogen degradation occurred at molar excess of
kininogens over the proteases in accordance with the lack of
staphopain activity inhibition by kininogens (unpublished
data). Collectively, the pattern and/or efficiency of the kinin-
ogen degradation corroborates well with VL activity gener-
ation by individual staphopains (Fig. 5), probably through
kinin release.
Identification of VL activity released from HK 
by staphopains
To identify a VL factors that was released from kininogens
by ScpA, we separated peptides that were cleaved from HK
by the proteinase and tested their VL activity. Only one pep-
tide (VL factor-1) that eluted at the same retention time as
BK had VL activity (Fig. 7). In addition, we found another
VL peptide (VL factor-2), which eluted later than BK, in the
HK sample that was preincubated with both staphopains
(Fig. 7). We detected no peptide and no VL activity from
HK that was treated with SspB alone (Fig. 7). These results
suggest that although SspB is far more efficient than ScpA in
degrading human kininogens (Fig. 6), this enzyme alone is
unable to release vasoactive peptides. Instead, by working in
concert, both staphopains generate the new VL peptide. Ap-
parently, this occurs through an ScpA-mediated cleavage of
HK- or LK-derived fragments that are produced by SspB, or
vice versa. The amino acid sequence of the VL factor-1
(RPPGFSPFR) was identical to that of BK. Conversely, VL
factor-2 had a primary structure that was equivalent to BK
but with three additional amino acid residues at the NH2
terminus (Leu-Met-Lys-BK). The cleavage site at the NH2
terminus of this peptide (-Ile-Ser-↓-Leu-Met-) is consistent
with the substrate specificity of SspB, which strongly prefers
a  -branched amino acid at the P2 position (unpublished
data). Synthetic Leu-Met-Lys-BK exhibited almost equal VL
activity as BK; the antagonist, HOE140, was able to inhibit
its activity completely (Fig. 8). No VL was elicited by the
scrambled peptide RGKRPLSFPFMP that has the same
amino acid composition as Leu-Met-Lys-BK (Fig. 8).
Blood pressure lowering by staphopains and kinins
To investigate further a link between staphopain-generated
kinin release and septic shock, we compared the effect of
staphopains and kinins on BP in guinea pigs. ScpA induced a
Figure 6. SDS-PAGE analysis of kininogen degradation by stapho-
pains. 1  g of LK (A and C) or HK (B and D) was incubated alone (lane 2), 
or with 0.02  g (lane 3), 0.1  g (lane 4), or 0.2  g (lane 5) of ScpA (A and 
B) or SspB (C and D). After 4 h, reaction was stopped by addition of staph-
ostatin (lane 6). (E) Purity of ScpA and SspB (lanes 7 and 8, respectively), 
loaded at 1  g. Lane 1, molecular weight standards.
Figure 7. VL activity of HK fragments produced by staphopains. 
180  l of HK 280  g/ml TBS was incubated with 20  l of 1  M ScpA 
(top), SspB (bottom), or both (middle) at 37 C for 10 min; fragments were 
separated with a C18 HPLC column. Each peak fraction was dried, dissolved 
in 100  l of TBS, and examined for VL activity. Solid lines, dashed lines, 
and solid bars denote absorbance at 280 nm, acetonitrile gradient, and VL 
activity, respectively. Arrows indicate elution retention time of kallidin (KL) 
or bradykinin (BK), respectively. DL, dye leakage.JEM VOL. 201, May 16, 2005 1673
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decrease of BP (by the mean BP 16.1   5.3 mm Hg; n   4)
that peaked 15 s after injection and returned to the initial
level 1 min later (Fig. 9 A). The effect was not induced by
enzymatically inactive ScpA (Fig. 9 B), and was inhibited
completely by HOE140 (Fig. 9 C). Synthetic Leu-Met-Lys-
BK exhibited almost equivalent BP-lowering activity as BK
(Fig. 8, D and E); they lowered the mean BP by 28.5   2.4
mm Hg and 32.6   2.9 mm Hg (n   4), respectively. In
contrast to the results of in vitro experiments, no significant
augmentation of ScpA-induced BP-lowering effect was ob-
served by simultaneous injection of SspB (unpublished data).
This most likely is due to immediate, more than 100-fold
enzyme dilution in the blood stream beyond the concentra-
tion that is needed for synergistic effect and/or SspB inhibi-
tion. Guinea pig plasma inhibitory activity for SspB is greater
than for ScpA (unpublished data).
DISCUSSION
An important pathophysiologic mechanism of septic shock is
hypovolemic hypotension that is caused by plasma leakage
into the extravascular space. The fact that ScpA induced VL
at a concentration as low as 20 nM within 5 min after injec-
tion into the guinea pig skin—with the reaction being aug-
mented by coexisting SspB (Figs. 1 and 2)—indicates that
VL induction by these proteinases can occur efficiently in
vivo. The extensive spreading of plasma leakage that is
caused by ScpA (Figs. 1 and 3) would facilitate further
plasma loss into the extravascular space. Moreover, the fast
generation of VL activity from human plasma by ScpA de-
creases the chance of enzyme clearance from the circulation
and suggests that these proteinases may cause septic shock in
cases of severe human S. aureus infection. The dependency
of staphopain VL activity on the BK B2-receptor (Figs. 2, 4,
and 5), or the presence of kininogen (Fig. 4), clearly showed
that this pathogenic activity is exerted by kinin production,
which is one of the prominent features of septic shock (3–8).
Furthermore, because staphopains also can act on LK—
whose plasma molar concentration is threefold greater than
HK (Fig. 5; reference 22)—they also have more opportunity
to interact with substrate than proteinases that generate BK
only from HK. Taken together, these results indicate that
VL induction by staphopains could be a new mechanism of
septic shock induction in severe S. aureus infection. This
contention is supported by the BP-lowering effect of ScpA,
which is dependent on the proteolytic activity of the enzyme
and the BK B2-receptor (Fig. 9).
The premise gains further credence in light of a study that
showed that heat-labile extracellular products of S. aureus, but
not heat-treated bacterium, exerted lethal activity in a mouse
sepsis model (14). This strongly argues against the importance
of heat-stable components of the S. aureus cell wall, including
teichoic acid and lipoteichoic acid as causative molecules of
septic shock, despite the fact that they can activate the plasma
kallikrein/kinin system (10). Moreover, in the mouse model,
the lethal event was not dependent on toxins, such as toxic
shock syndrome toxin 1, enterotoxins (A, B, and D), or
hemolysins ( ,  , and  ; reference 14). This implicates other
proteins that are secreted by S. aureus—especially proteolytic
enzymes—including epidermolytic toxins; the metalloprotein-
ase, aureolysin; the V8 proteinase; and the two staphopains.
The epidermolytic toxins, which are serine proteinases and
prefer glutamic acid at the P1 site, cause epidermal dissociation,
the pathologic hallmark of bullous impetigo and staphylococcal
scalded-skin syndrome; however, they do not trigger edema
when injected into newborn mouse skin (23) or guinea pig
skin (unpublished data), so they are unlikely to cause lethal sep-
sis. Conversely, hand-purified aureolysin and the V8 protease
did not increase vascular permeability, even at 3  M (unpub-
lished data). This leaves staphopains as the only major VL fac-
tors of S. aureus that are responsible for septic shock induction.
Kinin-releasing cysteine proteinases have been reported
from various sources, including cruzipain from Tripanosoma
Figure 8. VL activity of LMK-BK and effect of HOE140 on the 
activity. ( ,  ), LMK-BK; ( ,  ), BK; ( ), the scrambled peptide. Open 
and closed symbols denote VL activity in the absence or presence of 
HOE140 treatment. Values are means   SD (n   3). *P   0.01 for BK 
10 nM versus BK 1 or 100 nM and for LMK-BK 10 nM versus 100 nM. 
**P   0.02 for LMK-BK 1 nM versus 10 nM.
Figure 9. Blood pressure lowering activity of ScpA (6 nmol/200  l/kg 
body weight) and kinins (0.6 nmol/200  l/kg body weight). (A) ScpA. 
(B) ScpA treated with E64 (50  M). (C) ScpA in a guinea pig treated with 
HOE140 (10 nmol/kg body weight) 30 min before injection. (D) LMK-BK. (E) BK.S. AUREUS PROTEINASES INCREASE VASCULAR LEAKAGE | Imamura et al. 1674
cruzi (24), clostripain from Clostridium histolyticum (25), and
calpain from mammalian cells (26). Staphopains seem to be
far more potent than the Streptococcus pyogenes cysteine pro-
teinase (streptopain), which can also release kinins from hu-
man kininogens; however, the release of significant amount
of kinins in plasma requires a streptopain concentration of 1
 M and 60 min incubation (27). In contrast, a submicromo-
lar concentration of ScpA generates large amounts of kinin
from human plasma in just 5 min (Fig. 4). Thus far, stapho-
pains may be the most potent kinin-releasing cysteine pro-
teinases from gram-positive cocci-derived proteinases. Be-
cause edema is a common finding in the lesion of local S.
aureus infection (e.g., bullous impetigo), VL activity of sta-
phopains probably is involved in edema formation at in-
fected sites in addition to septic shock induction.
BK and kallidin (Lys-BK) are potent VL factors that are
released physiologically from HK and LK by plasma kal-
likreins and tissue kallikreins, respectively. It is generally ac-
cepted that these two kinins are active peptides that are gen-
erated in vivo. In this context, peptides that are released from
kininogens by bacterial proteinases were shown to act like ki-
nins by their VL activity and/or BK antigenicity—in most
cases without performing amino acid sequencing (16, 27).
The fact that Leu-Met-Lys-BK was released in the presence
of ScpA and SspB (Fig. 6) indicates that a combination of two
proteinases can generate a kinin through synergistically cleav-
ing kininogens at each terminal side of the kinin domain.
Previously, we found that two cysteine proteinases from Por-
phyromonas gingivalis (gingipains: RgpA and Kgp) released BK
from kininogens by cleaving the amino terminus by Kgp and
the carboxy terminus by RgpA (28). The mixture of human
neutrophil elastase and mast cell tryptase also produced BK
from HK (29). Therefore, it may be a common event in vivo
that two proteinases cooperatively generate a kinin, with one
proteinase cleaving kininogen at the amino terminus and the
other at the carboxy terminus. The carboxy terminal residues
of BK are required for the binding to the B2-receptor on the
cell (11), which is consistent with the finding that Leu-Met-
Lys-BK is as active as BK in VL activity (Fig. 8) and BP-low-
ering activity (Fig. 9). E-kinin (Ser-Leu-Met-Lys-BK-Ser-
Ser-Arg-Ile), which is released from kininogens by human
neutrophil elastase, and the related peptides Ser-Leu-Met-
Lys-BK-Ser-Ser and Ser-Leu-Met-Lys-BK can induce VL
and lower blood pressure in a B2-receptor–dependent man-
ner, but cannot cause smooth muscle contraction (30). This
suggests that additional residues at the carboxy-terminal side
of these peptides are trimmed off immediately, presumably in
the circulation, and convert the carboxy terminus to that
found in BK. Such trimming also could take place at the
amino terminus. Thus, some kinins that are generated by a
bacterial proteinase, or a combination of the two proteinases,
may contain the BK sequence with some additional residues
at either terminus. These BK-containing peptides are pro-
cessed finally in vivo to the functional kinin molecule, which
signals through the B2-receptor.
The promotion of leaked plasma that is spread by ScpA
(Figs. 1 and 3) may be due to connective tissue damage
through degradation of elastin (31), and possibly other extra-
cellular matrix proteins by ScpA. Another bacterial protease,
gingipain R, does not have any elastinolytic activity (not de-
picted) and the dye spread that accompanied the VL reaction
did not occur (Fig. 3). Alternatively, the effect can be ex-
erted by loosening a tight contact between epithelial cells.
Exposure of ScpA to a human airway epithelial cell line re-
sulted in a dramatic loss of intercellular adhesion of the
monolayer in an enzymatic activity-dependent manner (un-
published data). It is likely that ScpA causes destruction of
the interstitial tissue, which is filled with cells and substances
including adhesion proteins, bringing storage space of leaked
plasma. This may explain, in part, the steep dose-dependent
increase of ScpA VL activity (Fig. 2), whereas the VL is me-
diated by B2-receptor as is the VL by BK, whose VL activity
increases linearly (Fig. 2).
Conclusively, staphopains that are secreted from S. aureus
in the infected sites or in the circulation, are likely to produce
BK and Leu-Met-Lys-BK, and lead to septic shock through
their VL activity. This may be a new virulence mechanism
for this bacterium. The fact that the BP-lowering activity of
ScpA was not augmented by SspB in guinea pig does not ex-
clude the possibility that Leu-Met-Lys-BK can be formed in
human plasma devoid of SspB inhibitory activity. Because
Leu-Met-Lys-BK exerted comparative BP-lowering activity
with BK (Fig. 8), we suggest that the release of this new kinin
is a key event in the development of septic shock by S. au-
reus. Therefore, staphopains may constitute important thera-
peutic targets for S. aureus septic shock and inhibitors of these
enzymes—together with BK B2-receptor antagonists—could
be developed as drugs, particularly against antibiotic-resistant
strains (e.g., methicillin-resistant S. aureus).
MATERIALS AND METHODS
Materials. Human HK, factor XII, and prekallikrein were purchased from
Enzyme Research Laboratories. LK was purchased from Athens Research
Technology. Evans blue was obtained from Merck. Soybean trypsin inhibi-
tor (SBTI) was purchased from Sigma-Aldrich. BK, kallidin, and E-64, a
cysteine proteinase inhibitor, were obtained from the Peptide Institute. BK
B2-receptor antagonist, HOE140, was obtained from Hoechst AG. Other
chemicals were purchased from Wako Pure Chemicals. Plasmas that were
deficient in factor XII, prekallikrein, or kininogens were purchased from
George King Bio-Medical, Inc. Normal human plasma was prepared by
centrifugation of a mixture of nine volumes of freshly drawn blood from
healthy volunteers and one volume of 3.8% (wt/vol) sodium citrate.
Purification of staphopains and titration of their enzymatic activity.
Staphopains were purified from the culture media supernatants of S. aureus
strain V8-BC10 or 8325-4 as described previously (31). Purity of stapho-
pains was assessed by SDS-PAGE, mass spectroscopy, and NH2-terminal
amino acid sequence analysis. The enzymes were shown to be homogenous
proteins with a molecular mass of 21 kD (Fig. 6, panel E); this matched the
mass that was calculated from amino acid composition inferred from the
gene structure and known processing site of proenzymes (32). The active
site concentration of ScpA and SspB was determined by enzyme titration
with E-64 and staphostatins, respectively (31, 33).JEM VOL. 201, May 16, 2005 1675
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Treatment of plasmas and kininogens with staphopains. 45  l of
normal human plasma or plasma that was deficient in factor XII, prekal-
likrein, or kininogens and supplemented with 1 mM 1,10-phenanthroline
to inhibit kininases was incubated with 5  l of various concentrations of a
staphopain at 37 C for 5 min, followed by the addition of 50  l of 10 mM
Tris-HCl, pH 7.3, containing 150 mM NaCl (Tris-buffered saline [TBS])
supplemented with 0.1 mM E-64, 1 mM 1.10-phenanthroline, and 20  M
SBTI. 10  l of staphopain and 90  l of TBS which contained HK (80  g/
ml), LK (130  g/ml), or both was incubated at 37 C for 10 min; 5  l of 1
mM E-64 was added to stop the reaction.
Measurement of staphopain activity inhibition by kininogens. Staph-
opains at 10 nM final active enzyme concentration, as determined by active
site titration, were preincubated with 10-fold molar excess of LK or HK for
15, 60, and 120 min at 37 C. The residual enzyme activity was assayed with
azocoll or synthetic fluorogenic substrates as described previously (18, 20, 33).
SDS-PAGE analysis of kininogen degradation by staphopains. 1  g
of human LK or HK was incubated alone (controls) or with different amounts
(0.02–0.2  g) of purified staphopains in a total volume of 20  l of TBS for
4 h at 37 C. The reaction was stopped by the addition of 2  g of stapho-
statins, which are specific and very effective inhibitors of staphopains (33).
Samples were boiled under reducing conditions and analyzed using SDS-
PAGE (12% polyacrylamide gels; reference 34). Gels were silver stained.
VL assay. This experiment was performed according to the criteria of ani-
mal experiments of Kumamoto University Animal Experiment Committee
and was permitted by the Committee. Guinea pigs ( 350–450 g body
weight, both sexes) were anesthetized with an intramuscular injection of
ketamine (80 mg/kg body weight). 30 mg/kg body weight of Evans blue
(2.5% solution in 0.6% saline) was administered intravenously, followed by
an intradermal injection of 0.1 ml of test sample (dissolved in 10 mM PBS)
into the clipped flank of the guinea pig. After 10 min the guinea pig was
killed by bleeding; bluing tissues were cut out and incubated in 3 ml of for-
mamide at 60 C for 48 h. VL activity was determined by quantitatively
measuring the extracted Evans blue by absorbance at 620 nm as described
previously (21). Activity was expressed in terms of  g of dye extracted. The
activity of the buffer was subtracted from the activity of each sample.
HOE140 was injected subcutaneously to a guinea pig (10 nmol/kg body
weight) 30 min before intradermal injection of samples.
Measurement of dye leaked area. The length (A) and width (B) of a
blue spot were measured. The area was calculated by A/2   B/2   3.14.
Measurement of blood pressure. Guinea pigs ( 350–400 g body
weight, both sexes) were anesthetized with an intramuscular injection of
ketamine (100 mg/kg body weight) and ether inhalation. A blood pressure
transducer (MIKRO-TIP catheter transducer model SPR-671), connected
to a transducer amplifier (transducer control unit model TCB-500, Millar
Instruments) with a recorder (miniwriter WR7200, GRAPHTEC), was in-
serted into the left common carotid artery. Samples diluted with PBS were
administered in a single bolus injection into the left femoral vein.
Peptide separation. 180  l of HK (280  g/ml TBS) was incubated with
20  l of 1  M staphopain A at 37 C for 10 min, followed by the addition of
10  l of 1 mM E-64. An aliquot of the reaction mixture was applied on a
C18 HPLC column (4.6   150 mm; Yamamura Chemical Laboratories Co.
Ltd.) equilibrated with 0.1% TFA containing 16% acetonitrile, and eluted by
a linear gradient of acetonitrile to 24% for 30 min at a flow rate of 0.5 ml/
min. The HPLC was performed with a Hitachi model 655A; effluents were
monitored at 210 nm with a Hitachi model 655A-21 UV monitor. Each peak
fraction was dried, dissolved in 100  l of TBS, and examined for VL activity.
Amino acid sequence determination. Separated peptide peaks with VL
activity were subjected to an automated peptide sequencer (model 477A;
Perkin-Elmer/Applied Biosystems) equipped with an online phenylthiohy-
dantoin analyzer (model 120A; Perkin-Elmer/Applied Biosystems).
Peptide synthesis. LMKRPPGFSPFR (Leu-Met-Lys-BK) and its scram-
bled peptide, RGKRPLSFPFMP, were synthesized by the standard t-Boc
method using a solid-phase peptide synthesizer (model 430A; Perkin-
Elmer/Applied Biosystems) and purified by HPLC with a C8 column after
cleavage from the solid support and deprotection. Purity of the peptide
( 98%) was determined by HPLC and amino acid sequence analysis.
Statistics. Statistical analysis was performed using unpaired Student’s t test.
Values were expressed as means   SD in triplicate assay.
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